Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03033446
Recruitment Status : Recruiting
First Posted : January 26, 2017
Last Update Posted : May 3, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Centre, Singapore

Brief Summary:
The purpose of this study is to evaluate the effect of liver-localised radioembolization and nivolumab on liver cancer.

Condition or disease Intervention/treatment Phase
HepatoCellular Carcinoma Radiation: Y-90 Radioembolization Drug: Nivolumab Phase 2

Detailed Description:

The hypothesis is that liver-localized radioembolization will stimulate tumour and/or HBV specific T cell responses that are associated with favourable patient outcomes and that can be boosted using nivolumab anti-PD1 checkpoint blockade immunotherapy.

Primary objective

To evaluate the response rates of Y90 radioembolization in combination with nivolumab in HCC

Secondary objectives

  1. To evaluate time to response, response duration, time to treatment progression and sites of progression when RE is combined with nivolumab
  2. To assess progression free survival and overall survival when RE is combined with nivolumab
  3. To assess the quality of life using the FACT-HEP score and EORTC QLQ-C30
  4. To assess the safety and tolerability of the combination of RE and nivolumab

Exploratory objectives

  1. To evaluate the relationship between tumor biopsy PD-L1 expression and response to treatment with Y90 radioembolization in combination with nivolumab
  2. To assess relationship between blood lymphocyte (e.g., T cell) activation and phenotypic profiles with response to treatment with Y90 radioembolization in combination with nivolumab, using mass cytometry and fluorescence flow cytometry.
  3. To assess relationship between HCC tumour mutational burden and response to treatment with Y90 radioembolization in combination with nivolumab using whole-exome sequencing of tumour biopsy samples
  4. Where possible, to evaluate antigen-specific T cell responses to known HBV, HCC tumour (including candidate mutation-derived tumour neo-antigens) and other unrelated antigens (e.g. CMV, EBV, Influenza) in the blood and to assess kinetic changes in these responses associated with response to treatment with Y90 radioembolization in combination with nivolumab using mass cytometry and fluorescence flow cytometry.

Administration of study drug The first dose of nivolumab will be administered 21 days (+/- 3 days) after completion of RE. [The dose of Yttrium-90 will be determined as per institution norm by the Nuclear Medicine physician, based on factors such as the subject's Body Surface Area (BSA), the size of the tumour within the liver, and any dose modifications required for percent lung shunting between 10 - 20% on the Tc-99MMA scan].

The dose given will be intravenous 240mg absolute over 30 minutes. Subsequent doses of nivolumab will be administered in the outpatient setting at NCCS. After the first dose, intravenous nivolumab 240mg will be given every 2 weeks.

A US or CT guided liver biopsy will be conducted by an interventional radiologist on C1D8 Subjects will be assessed for the following at EVERY visit: physical examination, ECOG status, vital signs, Child-Pugh score and ALBI score CT or MRI scans to assess response to treatment will be done before cycle 4, 8, 12 and then after every 12 weeks thereafter (±7 days).

FACT-HEP and EORTC QLQ C30 version 3.0 questionnaire at cycle 4 and 8.

Follow-Up Visit will be done 2-3 months after last dose. Survival updates will be obtained by phone every 3-4 months after the follow-up visit and any new anti-cancer treatment given to the subject will be recorded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-Label, Single Centre, Non-Randomised Trial Of Y90-Radioembolization In Combination With Nivolumab In Asian Patients With Advanced Hepatocellular Carcinoma
Study Start Date : December 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Y90-Radioembolization and Nivolumab Radiation: Y-90 Radioembolization
Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
Other Name: Selective Internal Radiation Therapy

Drug: Nivolumab
21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
Other Name: Opdivo




Primary Outcome Measures :
  1. Response Rate [ Time Frame: Tumour assessment at 8 weeks ]

Secondary Outcome Measures :
  1. Time to Response [ Time Frame: From date of first dose with Y90 Radioemolization (RE) until best overall response of Complete Response (CR) or Partial Response (PR) is achieved, up to 12 weeks after last dose of Nivolumab ]
  2. Duration of Response [ Time Frame: From date of first assessment of CR or PR until the first date that progressive disease or death is documented, up to 2 years ]
  3. Time to Progression [ Time Frame: From date of first dose with Y90 RE until the first date that progressive disease is documented, up to 12 weeks after last dose of Nivolumab ]
  4. Progression Free Survival [ Time Frame: From date of first dose with Y90 RE until tumour progression, or death from any cause, up to 12 weeks after last dose of Nivolumab ]
  5. Overall Survival [ Time Frame: From date of first dose with Y90 RE until death from any cause, up to 2 years ]
  6. Quality of Life using the FACT-HEP score [ Time Frame: From date of screening until 3 months after last dose of Nivolumab ]
  7. Quality of Life using EORTC QLQ-C30 [ Time Frame: From date of screening until 3 months after last dose of Nivolumab ]
  8. Adverse events from the combination of RE and nivolumab assessed by NCI CTCAE v4.0 [ Time Frame: While receiving study agent and up to 100 days after last dose of Nivolumab ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with hepatocellular carcinoma (HCC) that is not suitable for resection or liver transplant, who are planned for Y90 radioembolization as per institutional practice.
  2. Patients must have measurable disease with target lesion in liver, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.
  3. Diagnosis of HCC confirmed by histology/cytology or clinically by AASLD criteria in cirrhotic subjects. Patients without cirrhosis require histological confirmation of diagnosis
  4. No prior Y90 radioembolization therapy. Prior local therapies, such as surgery, hepatic artery embolization/chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoabalastion is allowed, if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Local therapy must have been completed at least 4 weeks prior to the baseline scan
  5. Age ≥ 21 years.
  6. ECOG performance status ≤ 2
  7. Life expectancy of greater than 3 months
  8. Only patients with Child-Pugh score for liver cirrhosis of A (sum of scores for five parameters: 5-6) will be allowed into this trial
  9. Subjects with HBV infection must be on antiviral therapy per regional standard of care guidelines prior to initiation of study therapy. Both HBeAg positive and negative subjects will be included.
  10. Patients must have lesions in the liver that are amenable to CT-guided liver biopsy
  11. Patients must have normal organ and marrow function as defined below:

    • Haemoglobin ≥ 8.5g/dL
    • Absolute Neutrophil Count ≥ 1.5 x 10^9/L
    • Platelets ≥ 50 x 10^9/L
    • Total Bilirubin < 3 mg/dL
    • AST(SGOT)/ALT (SGPT) ≤ 3 x ULN
    • Creatinine ≤ 1.5 x ULN or measured/calculated Creatinine Clearance (CrCl) ≥ 60 ml/min
  12. Ability to understand and the willingness to sign a written informed consent document.
  13. Any surgery must be more than 28 days before start of study drug and any surgical wounds must be completely healed
  14. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to receiving the first dose of study medication, and must agree to adequate contraception use from time of signing the informed consent through to 120 days after the last dose of the study drug. Male subjects must agree to adequate contraception use from time of signing the informed consent through 120 days after the last dose of the study drug.

Exclusion Criteria:

  1. Patients are excluded if they are receiving any other investigational agents or using an investigational device within 4 weeks of first dose of treatment. Patients are excluded if they are receiving other systemic therapy within 2 weeks of first dose of treatment.
  2. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  3. Prior use of anti-PD1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any drug specifically targeted T-cell costimulatory checkpoint pathways
  4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements.
  5. Subjects with any active autoimmune disease or history of known or suspected autoimmune disease requiring systemic therapy within the past 2 years, except for subjects with vitiligo, resolved childhood asthma/atopy or euthyroid patients with a history of Grave's disease (subjects with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to randomization). Replacement therapy (e.g. with thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc) is not considered a form of systemic treatment
  6. Pregnant women or breastfeeding mothers are excluded from this study because of the potential risks to the foetus or baby. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  7. Diagnosis of immunodeficiency, including HIV/AIDS
  8. Prior organ allograft or allogeneic bone marrow transplantation
  9. History of severe hypersensitivity reactions to other monoclonal antibodies.
  10. Prisoners or subjects who are involuntarily incarcerated
  11. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
  12. Inability to comply with restrictions and prohibited activities/treatments in this study
  13. Chronic treatment with systemic steroids or other immunosuppressive agent.
  14. Subjects with concomitant second malignancies (except adequately treated non-melanomatous skin cancers, in situ cervical cancers, localized prostate cancer or in situ breast cancer) are excluded unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated to be required
  15. Prior radiation therapy to the liver or upper abdomen
  16. Inability to undergo Y-90 radioembolisation due to inability to cathterise the hepatic artery, portal vein thrombosis/occlusion limiting the ability to perform selective infusion, Tc-99M MAA scan showing unfavourable shunt fraction between the liver and pulmonary parenchyma, any other contraindications to RE as determined by the interventional radiologist (e.g. other anatomic variants precluding safe administration of Y90, severe peripheral vascular disease, uncorrectable coagulopathy etc)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03033446


Contacts
Layout table for location contacts
Contact: Su Pin Choo +65 6436 8000 choo.su.pin@singhealth.com.sg
Contact: Hui Shan Chong chong.hui.shan@nccs.com.sg

Locations
Layout table for location information
Singapore
National Cancer Centre - Singapore Recruiting
Singapore, Singapore, 169610
Contact: Choo Su Pin, MD    65-6436-8000      
Sponsors and Collaborators
National Cancer Centre, Singapore
Investigators
Layout table for investigator information
Principal Investigator: Su Pin Choo, MD National Cancer Centre, Singapore
Layout table for additonal information
Responsible Party: National Cancer Centre, Singapore
ClinicalTrials.gov Identifier: NCT03033446    
Other Study ID Numbers: CA209-678
First Posted: January 26, 2017    Key Record Dates
Last Update Posted: May 3, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents